August 29, 2007 — Roche Diagnostics said the U.S. Food and Drug Administration approved its biologics license for a test for direct detection of West Nile virus in donated human blood and plasma.
West Nile virus, which can cause serious health issues, is transmitted to humans most often through mosquito bites, but can also less commonly be transmitted by transfusion of infected blood or blood products. The test, called the cobas TaqScreen West Nile Virus Test, enables detection of the virus earlier in the infection cycle in donors who may show no symptoms of disease. According to the CDC, blood screening centers across the U.S. identified 340 donors whose blood tested positive for West Nile virus in 2006, and 23 to date in 2007.
"We are pleased to offer U.S. blood banks a new choice for both maximizing blood safety and optimizing efficiency," said Daniel O'Day, head of Roche Molecular Diagnostics which developed the test. "The Roche test, run under an investigational new drug application by 14 clinical trial sites testing blood from a network of more than a 100 donation centers, helps blood banks streamline workflow and improve test results accuracy with reduced hands-on time, ready-to-use reagents, and full automation of each step."
The test is designed to run on the cobas s 201 system, Roche's flexible, modular instrument platform, which automates each step of the real-time PCR blood screening process. The test uses Roche's highly sensitive polymerase chain reaction technology (PCR), a nucleic acid amplification technology, to detect the genetic material of the West Nile virus directly in blood. The CDC has stated that screening donated blood for West Nile virus by nucleic acid amplification tests has markedly reduced the risk of transfusion transmission.
Most people infected with West Nile Virus never show signs of illness, or they only experience several days of flu-like symptoms. Others, especially those with compromised immune systems, can suffer serious, and in some cases, life threatening reactions. In 2002, the CDC says transfusion-associated transmission (TAT) of West Nile virus infection acquired through blood transfusion marked the emergence of a new threat to the U.S. blood supply. Although mosquito-borne transmission remains the predominant mode of West Nile transmission, identification of TAT underscored the need for screening of donated blood for the virus. In June 2003, blood-collection agencies implemented investigational West Nile nucleic acid-amplification tests (NATs) to screen all blood donations and identify potentially infectious donations for quarantine and retrieval. This screening was performed on approximately 6 million units during June-December 2003, resulting in the removal of at least 818 West Nile contaminated blood donations from the blood supply in 2003 alone.

For more information: www.roche.com

Related Content

News | Proton Therapy

June 24, 2021 — Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G ...

Time June 24, 2021
arrow
News | Linear Accelerators

June 18, 2021 — Elekta announced that its Elekta Harmony radiation therapy system recently received U.S. FDA 510(k) ...

Time June 18, 2021
arrow
News | Linear Accelerators

January 20, 2021 — A joint team of researchers from Radiation Oncology at Dartmouth's and Dartmouth-Hitchcock's Norris ...

Time January 20, 2021
arrow
News | Linear Accelerators

January 4, 2021 — RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular ...

Time January 04, 2021
arrow
News | Radiation Oncology

April 17, 2020 — PTW has installed the first Beamscan MR motorized 3-D water phantom in North America at the Princess ...

Time April 17, 2020
arrow
News | Radiation Oncology

January 30, 2020 — Elekta announced that it signed a contract with the Institut Jules Bordet, Brussels, for an Elekta ...

Time January 30, 2020
arrow
Technology | Quality Assurance (QA)

IBA Dosimetry GmbH announced the launch of the new enhanced myQA Machines 2019 software environment at the upcoming American Society for Radiation Oncology (ASTRO) congress, Sept. 15-19 in Chicago.

Time September 12, 2019
arrow
Videos

Kristin Higgins, M.D., medical director of radiation oncology at the Emory Clinic at the Winship Cancer Institute, and ...

Time October 29, 2018
arrow
News | Radiation Therapy

Gustave Roussy has awarded Elekta with an order for four Versa HD linear accelerators, replacing their existing installed base of competing systems. The premier European comprehensive cancer center started its radiotherapy program in 2013.

Time September 04, 2015
arrow
News

The ECRI Institute released a new techIQ brief on key factors to consider when purchasing a linear accelerator (linac) for external beam radiation therapy. The report is a compilation of results from a survey of hundreds of users of linac-based radiosurgery systems; participants were asked to rate the functions and features of the four major linac vendors: Accuray, Brainlab, Elekta and Varian Medical Systems.

Time June 23, 2015
arrow
Subscribe Now